UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  March 1, 2005

 

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-26642

 

87-0494517

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

320 Wakara Way

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (801) 584-3600

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

ITEM 8.01             Other Events

 

                On March 1, 2005, Myriad Genetics, Inc. announced that it submitted an Investigational New Drug (IND) application to the FDA to begin a second Phase I human clinical trial with MPC-6827 to evaluate the potential of MPC-6827 to treat metastatic brain cancer.  The press release is attached hereto as an exhibit to this Current Report on Form 8-K and is being filed pursuant to this Item 8.01 as Exhibit 99.1 to this Current Report on Form 8-K.

 

ITEM 9.01             Financial Statements and Exhibits.

 

                (c)           The following exhibit is filed with this report:

 

Exhibit

Number

 

Description

 

 

 

99.1

 

The Registrant’s press release dated March 1, 2005.

 

2


 

SIGNATURES

 

                Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

MYRIAD GENETICS, INC.

 

 

 

Date: March 1, 2005

By: 

/s/ Peter D. Meldrum

 

 

 

Peter D. Meldrum

 

 

President and Chief Executive Officer

 

3


 

                                                                                         EXHIBIT INDEX

 

Exhibit

Number

 

Description

 

 

 

99.1

 

The Registrant’s press release dated March 1, 2005.

 

4